Search
ell
eng
ell
eng
Menu
Home
About Us
History
Products
Careers
News
Contact Us
Home
News
Home
News
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in
Read more
The Dates of the XXVII Edition of the International Fair Play Menarini Awards
Read more
O Γρηγόρης Πολίτης νέος Διευθύνων Σύμβουλος της Μenarini Hellas
Read more
Menarini Hellas 1989-2023 Γεώργιος Συκιανάκης: «Ολοκλήρωση μιας επιτυχημένης συνεργασίας»
Read more
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
Read more
1
2
3
4
5